FURTHER INFORMATION ABOUT OUR COMPANY

1. Incorporation of Our Company

Our Company was established as a limited liability company in the PRC on September 21, 2007 and was converted into a joint stock company with limited liability on June 20, 2018 under the laws of the PRC and completed the listing of our A Shares on the Shanghai Stock Exchange STAR Market (stock code: 688108) on October 30, 2019. As of the Latest Practicable Date, the registered share capital of our Company was RMB417,952,000 divided into 417,952,000 Shares with a nominal value of RMB1.00 each. This includes 910,000 A Shares repurchased by our Company pursuant to repurchase mandates approved by our Board and held in our Company's stock repurchase account as treasury shares.

Our Company has established a place of business in Hong Kong at 16th Floor, Wing On Centre 111 Connaught Road Central, Hong Kong, and has registered as a non-Hong Kong company in Hong Kong under Part 16 of the Companies Ordinance on May 22, 2026. Ms. Vincci Chan, the joint company secretary of our Company, has been appointed as our authorized representative for the acceptance of service of process in Hong Kong whose correspondence address is the same as our place of business in Hong Kong.

2. Changes in Share Capital of Our Company

On September 21, 2007, our Company was established as a limited liability company with a registered capital of USD8,000,000.

On August 22, 2024, the share capital of our Company increased from RMB41,000,000 to RMB413,456,000, comprising 413,456,000 A Shares with a nominal value of RMB1.00 each in relation to the ungranted shares under the employee incentive scheme.

On December 18, 2025, the share capital of our Company increased from RMB413,456,000 to RMB416,048,000, comprising 416,048,000 A Shares with a nominal value of RMB1.00 each in relation to the ungranted shares under the employee incentive scheme.

On March 3, 2026, the share capital of our Company increased from RMB416,048,000 to RMB417,952,000.

For further details, see "History, Development and Corporate Structure" in this document. Save as disclosed above, there has been no alteration in our share capital within two years immediately preceding the date of this document.

3. Changes in the Share Capital of Our Subsidiaries

Our subsidiaries as of the Latest Practicable Date are set out in note 15 to the Accountants' Report.

SINOMED Hong Kong

On January 26, 2026, the registered capital of SINOMED Hong Kong was increased from USD29,458,618 to USD37,270,341.

Nova Vascular Inc.

On July 28, 2025, the registered capital of Nova Vascular Inc. was increased from USD15,700,000 to USD18,200,000.

Save as disclosed above, there has been no alteration in the total issued share capital of our subsidiaries during the two years immediately preceding the date of this document.

4. Resolutions of the Shareholders

Pursuant to a Shareholders' meeting of our Company held on April 17, 2026, the following resolutions, among others, were passed by our Shareholders:

(a) the **[REDACTED]** by our Company of H Shares of a nominal value of RMB1.00 each and that such H Shares be **[REDACTED]** on the **[REDACTED]**;

(b) that the number of H Shares to be **[REDACTED]** shall not be more than **[REDACTED]**% of the total issued share capital of our Company as enlarged by the **[REDACTED]** (without taking into account the H Shares which may be **[REDACTED]** and **[REDACTED]** pursuant to the exercise of the **[REDACTED]**), and the **[REDACTED]** to the **[REDACTED]** (or their representatives) of the **[REDACTED]** of not more than **[REDACTED]**% of the number of H Shares **[REDACTED]** pursuant to the **[REDACTED]**;

(c) subject to the completion of the **[REDACTED]**, the adoption of the Articles of Association which shall become effective on the **[REDACTED]**, and the authorization to the Board to amend the Articles of Association in accordance with the requirements of the relevant laws and regulations and the Listing Rules; and

(d) authorization of our Board to handle all relevant matters relating to, among other things, the **[REDACTED]** and **[REDACTED]** of the H Shares.

FURTHER INFORMATION ABOUT THE BUSINESS OF OUR COMPANY

1. Summary of Material Contract

We have entered into the following contract (not being a contract entered into in the ordinary course of business) within the two years immediately preceding the date of this document that is or may be material:

(a) the **[REDACTED]**;

2. Intellectual Property Rights

(a) Trademarks

As of the Latest Practicable Date, we have registered the following trademarks which we consider to be material to our business:

No.	Owner	Registration No.	Place of Registration	Trademark	Class	Expiry Date
1	the Company	25133592	PRC	Tytrak	10	13/7/2028
2	the Company	25133588	PRC	NC Thonic	10	13/7/2028
3	the Company	25133585	PRC	Neuro RX	10	13/7/2028
4	the Company	15914695	PRC	BuMA Supreme	10	13/2/2036
5	the Company	10672681	PRC	赛诺医疗	10	20/5/2033
6	the Company	10672680	PRC	SINOMED	10	20/5/2033
7	the Company	10515305	PRC	赛诺医疗	42	20/6/2033
8	the Company	10515304	PRC	SINOMED	42	13/4/2033
9	the Company	9277224	PRC	BuMA	10	13/4/2032
10	the Company	9267069	PRC	SINOMED 赛诺医疗	42	20/6/2032
11	the Company	6315911	PRC	赛诺	10	13/2/2030
12	the Company	36918455	PRC	Neuro LPS	10	6/12/2029
13	the Company	51896259	PRC	HT	10	6/3/2032
14	the Company	66603802	PRC	HT Infinity	10	13/2/2033
15	the Company	66962886	PRC	速普瑞	10	27/2/2033
16	the Company	68525474	PRC	SEAWHALE 海鲸	10	20/8/2033
17	the Company	68532151	PRC	跃豚	10	13/6/2033
18	the Company	68534106	PRC	海神戟	10	13/6/2033
19	the Company	68244705	PRC	NC ROCKSTAR	10	27/5/2033
20	the Company	68248932	PRC	SC HONKYTONK	10	27/5/2033
21	the Company	66974581	PRC	复鈊	10	20/12/2033
22	the Company	70711858	PRC	马利亚纳	10	13/10/2033
23	SINOMED Neurovita	84244587	PRC	COVESTAR	10	13/9/2035
24	SINOMED Neurovita	77472663	PRC	COMETIU	10	27/10/2035
25	SINOMED Neurovita	74518496	PRC	APEX TRA GC	10	6/5/2034
26	SINOMED Neurovita	74530973	PRC	COMETIU	10	13/4/2034
27	SINOMED Neurovita	74518500	PRC	APEX TRA SYSTEM	10	6/5/2034

No.	Owner	Registration No.	Place of Registration	Trademark	Class	Expiry Date
28	SINOMED Neurovita	73662838	PRC	Rayline	10	13/3/2035
29	SINOMED Neurovita	69848369	PRC	APEX TRA	10	20/8/2033
30	SINOMED Neurovita	69860538A	PRC	Rayline	10	6/11/2033
31	SINOMED Neurovita	69846500	PRC	Apachi	10	20/8/2033
32	SINOMED Neurovita	69844538	PRC	NOVARAIL	10	20/8/2033
33	SINOMED Neurovita	69860538	PRC	Rayline	10	6/10/2034
34	SINOMED Neurovita	66469368	PRC	GHUNTER	10	6/2/2033
35	SINOMED Neurovita	65583799	PRC	LEATUBE	10	20/12/2032
36	SINOMED Neurovita	65295117	PRC	TORR	10	13/2/2033
37	SINOMED Neurovita	62123086	PRC	TORR	10	13/10/2032
38	SINOMED Neurovita	58112759	PRC	NOVADES	10	6/2/2032
39	SINOMED Neurovita	49790397	PRC	Neurovita	10	6/6/2031
40	SINOMED Neurovita	49803932	PRC	神畅	10	6/6/2031
41	SINOMED Neurovita	49803932	PRC	神畅	42	6/6/2031
42	SINOMED Neurovita	49790397	PRC	Neurovita	42	6/6/2031

(b) Domain Names

As of the Latest Practicable Date, we have registered the following domain names which we consider to be material to our business:

No.	Owner	Domain name	Expiry Date
1	the Company	sinomed.com	9/2/2029
2	the Company	sinomed.net	27/6/2029
3	the Company	sinomedical.net	3/8/2029

(c) Copyrights

As of the Latest Practicable Date, we have no copyright which we consider to be material to our business.

(d) Patents

As of the Latest Practicable Date, we have registered the following patents which we consider to be material to our business:

No.	Owner	Type	Patent	Registration No.	Application Date	Expiry Date	Place of Application
1	AlchiMedics, Alchimer	Invention	Formation of organic electro-grafted films on the surface of electrically conductive or semi-conductive surfaces	US8784635B2	28/2/2007	16/3/2032	United States
2	AlchiMedics	Invention	Formation of organic electro-grafted films on the surface of electrically conductive or semi-conductive surfaces	US9863052B2	28/2/2007	9/6/2028	United States
3	AlchiMedics	Invention	Formation of organic electro-grafted films on the surface of electrically conductive or semi-conductive surfaces	US10851466B2	28/2/2007	23/10/2027	United States
4	AlchiMedics	Invention	Formation of organic electro-grafted films on the surface of electrically conductive or semi-conductive surfaces	US12077878B2	28/2/2007	23/10/2027	United States
5	AlchiMedics	Invention	Formation of organic electro-grafted films on the surface of electrically conductive or semi-conductive surfaces	US12509791B2	28/2/2007	28/2/2027	United States
6	Alchimer, the Company	Invention	Method for forming an organic electro-grafted thin film on a conductive or semiconductive surface	CN101213264B	28/2/2007	28/2/2027	PRC
7	AlchiMedics	Invention	Drug eluting stent with a biodegradable release layer attached with an electro-grafted primer coating	US9884142B2	13/6/2007	26/3/2028	United States

No.	Owner	Type	Patent	Registration No.	Application Date	Expiry Date	Place of Application
8	the Company	Invention	Drug eluting stent and method of use of the same for enabling restoration of functional endothelial cell layers	US11039942B2	13/6/2007	11/11/2027	United States
9	the Company	Invention	Drug eluting stent and method of use of the same for enabling restoration of functional endothelial cell layers	US11660214B2	13/6/2007	6/12/2027	United States
10	the Company	Invention	Drug-eluting stent with a biodegradable release layer attached to an electro-grafted base coating	CN101346156B	13/6/2007	13/6/2027	PRC
11	the Company	Invention	Drug-eluting stent and method for using the same to restore a functional endothelial cell layer	CN108551759B	30/10/2017	30/10/2037	PRC
12	the Company	Invention	Drug eluting stent and method of use of the same for enabling restoration of functional endothelial cell layers	US11969528B2	30/10/2017	30/10/2037	United States
13	SINOMED Neurovita	Invention	Intracranial drug-eluting stent system and method for preparing the same	CN105833358B	28/4/2016	28/4/2036	PRC
14	SINOMED Neurovita	Invention	Self-expanding drug-coated vascular stent	CN115429507B	3/6/2021	3/6/2041	PRC

No.	Owner	Type	Patent	Registration No.	Application Date	Expiry Date	Place of Application
15	SINOMED Neurovita, The First Affiliated Hospital of Navy Medical University of the People's Liberation Army of China	Invention	Self-expanding drug-eluting stent system and method for preparing the same	CN115671407B	25/10/2022	25/10/2042	PRC
16	the Company, SINOMED Neurovita	Invention	Coated flow diverter device and method for preparing the same and use thereof	CN115836896B	21/2/2023	21/2/2043	PRC
17	the Company	Invention	Low-profile heart valve and delivery system	CN109843218B	4/12/2017	4/12/2037	PRC
18	the Company	Invention	low profile heart valve and delivery system	JP7057350B2	4/12/2017	4/12/2037	Japan
19	the Company	Invention	low profile heart valve and delivery system	EP3503849B1	4/12/2017	4/12/2037	Europe
20	the Company	Invention	Transapical mitral valve implantation device	CN108578016B	26/4/2018	26/4/2038	PRC
21	the Company	Invention	Transapical mitral valve implantation device	EP3785669B1	6/12/2018	6/12/2038	Europe
22	the Company	Invention	Transapical implantable mitral valve device	US12318282B2	6/12/2018	16/3/2041	United States
23	the Company	Invention	Transapical mitral valve implantation device	JP7417539B2	6/12/2018	6/12/2038	Japan
24	the Company	Invention	Mitral valve stent	CN113967104B	23/7/2020	23/7/2040	PRC
25	the Company	Invention	Apparatus and method for treating native valve leaflets in human heart	JP7820541B2	29/12/2022	29/12/2042	Japan

Save as disclosed above, as of the Latest Practicable Date, there was no other trade or service mark, patent, intellectual or industrial property right which was material in relation to our business.

DISCLOSURE OF INTERESTS

1. Disclosure of Interests of Directors and Chief Executive of the Company

Immediately following the completion of the **[REDACTED]** (assuming the **[REDACTED]** is not exercised), the interests and/or short positions (as applicable) of the Directors and the chief executive of the Company in the Shares, underlying Shares and debentures of the Company and any interests and/or short positions (as applicable) in shares, underlying shares or debentures of any of the associated corporations of the Company (within the meaning of Part XV of the SFO) which (1) will have to be notified to the Company and the **[REDACTED]** pursuant to **[REDACTED]** of the SFO (including interests and/or short positions (as applicable) which they are taken or deemed to have under such provisions of the SFO), (2) will be required, pursuant to **[REDACTED]** of the SFO, to be entered in the register referred to therein or (3) will be required, pursuant to the **[REDACTED]** as set out in **[REDACTED]** to the **[REDACTED]**, to be notified to the Company and the **[REDACTED]**, in each case once the H Shares are **[REDACTED]** on the **[REDACTED]**, will be as follows:

(i) Interests in the Company

Name	Position	Capacity/ nature of interest	Number of Shares held	Approximate percentage of shareholding in our A Shares after the [REDACTED][1]	Approximate percentage of shareholding in the total issued share capital of our Company after the [REDACTED][1]
				(%)	*(%)*
Dr. Sun[2]	Executive Director, chairman of our Board and general manager	Interest in controlled corporations;	**[REDACTED]** A Shares	**[REDACTED]**	**[REDACTED]**
		Interest of spouse	**[REDACTED]** A Shares	**[REDACTED]**	**[REDACTED]**
Mr. Huang Kai[3] .	Executive Director and board secretary	Beneficial owner;	**[REDACTED]** A Shares	**[REDACTED]**	**[REDACTED]**
		Interest in controlled corporation	**[REDACTED]** A Shares	**[REDACTED]**	**[REDACTED]**
Mr. Kang Xiaoran[4]	Executive Director and deputy general manager	Beneficial owner;	**[REDACTED]** A Shares	**[REDACTED]**	**[REDACTED]**
		Interest in controlled corporation	**[REDACTED]** A Shares	**[REDACTED]**	**[REDACTED]**
Ms. Chen Lin . . .	Executive Director and senior human resources director	Beneficial owner	**[REDACTED]** A Shares	**[REDACTED]**	**[REDACTED]**

Notes:

(1) The calculation is based on the total number of **[REDACTED]** A Shares in **[REDACTED]** and **[REDACTED]** H Shares (assuming the **[REDACTED] [REDACTED]** is not exercised) in **[REDACTED]** upon **[REDACTED]**.

(2) For details of interests of Dr. Sun, see the section headed "Substantial Shareholders" in this Document.

(3) As of the Latest Practicable Date, Mr. Huang Kai is the general partner of Yangguang Yongye.

(4) As of the Latest Practicable Date, Mr. Kang Xiaoran is the general partner of Yangguang Fuye.

(ii) Interests in the associated corporation of the Company

Name of Director or chief executive	Name of associated corporation	Nature of interest	Shareholding
Dr. Sun(1)	SINOMED Neurovita	Interest in controlled corporations	5.58%
Mr. Kang Xiaoran(2)	SINOMED Neurovita	Interest in controlled corporation	2.28%
Mr. Huang Kai(3)	SINOMED Neurovita	Interest in controlled corporations	3.50%

Notes:

(1) As of the Latest Practicable Date, Dr. Sun held approximately 61.78% and 99.84% of the partnership interest in Jingye Yangguang and Longye Yangguang. Jingye Yangguang and Longye Yangguang held 2.96% and 2.62% equity interest in SINOMED Neurovita, respectively. Under SFO, Dr. Sun is deemed to be interested in the entire Shares held by these partnerships.

(2) As of the Latest Practicable Date, Mr. Kang Xiaoran held approximately 44.65% of the partnership interest in Xiye Yangguang. Under SFO, Mr. Kang Xiaoran is deemed to be interested in the entire Shares held by Xiye Yangguang.

(3) As of the Latest Practicable Date, Mr. Huang Kai serves as the general partner of Longye Yangguang and held 36.20% of the partnership interest in Hongye Yangguang. Longye Yangguang and Hongye Yangguang held 2.62% and 0.88% equity interest in SINOMED Neurovita, respectively. Under SFO, Mr. Huang Kai is deemed to be interested in the entire Shares held by these partnerships.

Save as disclosed above, so far as the Directors are aware, immediately following the completion of the **[REDACTED]**, no Directors or the chief executive will, directly or indirectly, be interested in the Shares, underlying Shares and debentures of the Company or the shares, underlying shares or debentures of any of the associated corporations of the Company.

2. Disclosure of Interests of Substantial Shareholders

(i) Interests in the Company

Save as disclosed in "Substantial Shareholders" in this document and " — Disclosure of Interests of Directors and Chief Executive of the Company — (i) Interests in the Company" in this section, the Directors are not aware of any person who will have an interest or a short position in the Shares or underlying Shares of the Company which would fall to be disclosed to the Company under the provisions of **[REDACTED]** of the SFO.

(ii) Interests in other members of the Group

The Directors are not aware of any person who will be, directly or indirectly, interested in 10% or more of the issued voting shares of any other members of the Group.

3. Service Contracts

Each of our Directors has entered into a service contract with our Company. The principal particulars of these service contracts comprise (a) a term of office commencing on the date of the approval at the relevant Company's general meeting and ending on the expiration of the term of office of the prevailing session of the Board; and (b) termination provisions in accordance with their respective terms.

Save as disclosed above, none of our Directors has or is proposed to have entered into any service contract with any member of our Group (excluding contracts expiring or determinable by any member of our Group within one year without payment of compensation other than statutory compensation).

4. Remuneration of Directors

Save as disclosed in the section headed "Directors and Senior Management" in this document and note 8 to the Accountants' Report, for the years ended December 31, 2023, 2024 and 2025, none of our Directors received other remunerations of benefits in kind from us.

5. Type II Restricted Share Incentive Plan

The following is a summary of the principal terms of our 2022 Type II Restricted Share Incentive Plan. The terms of 2022 Type II Restricted Share Incentive Plan are not subject to the provisions of Chapter 17 of the Listing Rules as they do not involve any grant of Type II restricted Shares by our Company after our **[REDACTED]**. Save as otherwise disclosed, the terms of the 2022 Type II Restricted Share Incentive Plan are summarized below.

(a) Purpose

The purpose of the 2022 Type II Restricted Share Incentive Plan is to further improve the Group's long-term incentive mechanism, attract and retain outstanding talents, fully mobilize the enthusiasm of the Group's employees and enable all parties to jointly focus on the long-term development of the Group. The 2022 Type II Restricted Share Incentive Plan is implemented to align the interests of our Shareholders with the interests of our Group and employees.

(b) Administration

The 2022 Type II Restricted Share Incentive Plan are subject to the approval of the Shareholders' meeting, the administration of our Board and the supervision of independent Directors of our Company.

(c) Participants

The participants of our 2022 Type II Restricted Share Incentive Plan include our Directors, senior management and core technical staff and key employees.

(d) Source and Maximum Number of Shares

The Shares underlying the 2022 Type II Restricted Share Incentive Plan are the A Shares to be issued by our Company. The restricted Shares are subject to a vesting period and will only be vested upon fulfilling the vesting conditions stipulated. The maximum number of restricted Shares that can be granted under the 2022 Type II Restricted Share Incentive Plan is as follows:

Type II Restricted Share Incentive Plan	Maximum number of restricted Shares to be granted under the Plan
2022 Type II Restricted Share Incentive Plan	18,750,000

(e) Date of Grant and Term of the 2022 Type II Restricted Share Incentive Plan

The date on which the restricted Shares are granted shall be determined by the Board after the approval of the Type II Restricted Share Incentive Plan by the Shareholders' meeting and shall be a trading day. Under our 2022 Restricted Share Incentive Plan, the grant of restricted Shares shall be completed and announced within 60 days after the approval of such plans by the Shareholders' meeting.

The 2022 Type II Restricted Share Incentive Plan shall be effective from the date of the initial grant of restricted Shares under such plan up to the date when all of the restricted Shares granted under the plans have been vested or void and lapsed, provided that the term of the plan shall not exceed 60 months.

(g) Conditions to the Grant of Restricted Shares

The restricted Shares under the 2022 Type II Restricted Share Incentive Plan shall be granted to selected participants subject to the fulfillment of the following conditions:

(i) with respect to our Company, none of the following circumstances having occurred:

1) an audit report with an adverse opinion or a disclaimer of opinion has been issued by the reporting accountant with respect to our Company's accountant's report for the most recent fiscal year;

2) an audit report with an adverse opinion or a disclaimer of opinion has been issued by the reporting accountant with respect to the internal control of the financial report for the most recent fiscal year;

3) our Company has not distributed dividends in accordance with the laws and regulations, our Articles of Association or our public commitment within the last 36 months after its listing;

4) applicable laws and regulations prohibit the implementation of share incentive; or

5) other circumstances determined by the CSRC; and

(ii) with respect to a grantee, none of the following circumstances having occurred:

1) the grantee has been regarded as an inappropriate person by the stock exchange within the last 12 months;

2) the grantee has been regarded as an inappropriate person by the CSRC and its local office within the last 12 months;

3) the grantee has received administrative penalty or been prohibited from entering into the securities market by the CSRC and its local office due to material non-compliance with applicable laws and regulations within the last 12 months;

4) the grantee is not qualified to serve as a director or senior management according to the PRC Company Law;

5) the grantee is prohibited from participating in any share incentive of listed companies according to applicable laws and regulations; or

6) other circumstances determined by the CSRC.

(h) Vesting of Type II Restricted Shares

The restricted shares will be vested in three tranches with a ratio of 40%, 30% and 30% on a date within each of the three vesting periods in accordance with the vesting schedule set out under the 2022 Type II Restricted Share Incentive Plan as follows:

(a) between the first trading date after the 12-month anniversary from the date of grant and the last trading day up to the 24-month anniversary of the date of grant;

(b) between the first trading date after the 24-month anniversary from the date of grant and the last trading day up to the 36-month anniversary of the date of grant; or

(c) between the first trading date after the 36-month anniversary from the date of grant and the last trading day up to the 48-month anniversary of the date of grant.

Vesting of the restricted shares shall be subject to fulfillment of each of the following conditions: (1) the conditions set out under paragraph (vii) above are fulfilled; (2) the grantee remains in a continuous employment relationship with the Group for at least 12 months immediately preceding each of the vesting dates and (3) the annual assessment of the grantee and performance targets of the Company as set out under the Type II Restricted Share Incentive Plan are achieved.

The grant price of shall be determined by the Board on a discretionary basis, subject to a minimum grant price of RMB3.00 per Share, and with reference to the closing price of the Company's shares on the date of grant.

(i) Lock-up for Directors and the senior management team

If the grantee is a Director or a senior management of our Company, the number of Shares which can be transferred in each year shall not exceed 25% of the total number of Shares that he or she holds during the period of the employment. No share held by such Director or senior management can be transferred within six months after the termination of his or her employment. If the grantee is a Director or senior management of our Company, any gains arising from the sale of Shares within six months of the purchase or through purchase of Shares within six months of the sale shall belong to our Company and given up to the Board. The grantee shall comply with any change in the applicable laws and regulations on the foregoing lock-up requirements from time to time.

6. Disclaimers

(a) Save as disclosed in this section and the section headed "History, Development and Corporate Structure" in this document, none of our Directors or any of the parties listed in the paragraph headed "— Other Information — 5. Qualifications of Experts" in this Appendix is:

(i) interested in our promotion, or in any assets which have been, within two years immediately preceding the date of this document, acquired or disposed of by or leased to us, or are proposed to be acquired or disposed of by or leased to any member of our Company; or

(ii) materially interested in any contract or arrangement subsisting at the date of this document which is significant in relation to our business.

(b) Save in connection with the **[REDACTED]** and the **[REDACTED]**, none of the parties listed in the paragraph headed "— Other Information — 5. Qualifications of Experts" in this Appendix.

(i) is interested legally or beneficially in any shares in any member of our Group; or

(ii) has any right (whether legally enforceable or not) to **[REDACTED]** for or to nominate persons to **[REDACTED]** for any securities in any member of our Group;

(c) Save as disclosed in this section and the section headed "Directors and Senior Management" in this document, none of our Directors is a director or employee of a company that has an interest in the share capital of our Company which, once the H Shares are **[REDACTED]** on the **[REDACTED]**, would have to be disclosed pursuant to **[REDACTED]** of the SFO.

(d) So far as is known to our Directors, none of our Directors or their respective close associates (as defined under the **[REDACTED]**) or Shareholders who owns more than 5% of the issued shares of our Company has any interests in the five largest customers or the five largest suppliers of our Group.

OTHER INFORMATION

1. Estate Duty

Our Directors have been advised that no material liability for estate duty is likely to impose on our Company or any of our subsidiaries under the laws of the PRC.

2. Litigation

As of the Latest Practicable Date, no member of our Group was involved in any litigation, arbitration or claim of material importance, and, so far as we are aware, no litigation, arbitration or claim of material importance is pending or threatened against any member of our Group, which would have a material adverse effect on our financial condition or results of operations, taken as a whole.

3. Sole Sponsor

The Sole Sponsor have made an application on behalf of our Company to the **[REDACTED]** for the **[REDACTED]** of, and permission to **[REDACTED]**, our H Shares. All necessary arrangements have been made to enable the securities to be admitted into **[REDACTED]**.

The Sole Sponsor satisfies the independence criteria applicable to sponsors set out in Rule 3A.07 of the Listing Rule. The Sole Sponsor will receive a fee of US$600,000 to act as a sponsor to our Company in connection with the **[REDACTED]**.

4. Preliminary Expenses

As of the Latest Practicable Date, our Company has not incurred material preliminary expenses.

5. Qualifications of Experts

The qualifications of the experts (as defined under the Listing Rules and the Companies (Winding Up and Miscellaneous Provisions) Ordinance) who have given opinions and/or advice in this document are as follows:

Name	Qualifications
CMB International Capital Limited	Licensed corporation to conduct Type 4 (advising on securities) and Type 6 (advising on corporate finance) regulated activities under the SFO
BDO Limited	Certified Public Accountants under Professional Accountants Ordinance (Cap. 50) and Registered Public Interest Entity Auditor under Financial Reporting Council Ordinance (Cap. 588)
Zhong Lun Law Firm	Company's PRC Legal Adviser
China Insights Consultancy	Independent industry consultant

6. Consents

Each of the experts as referred to in the paragraph headed "— Other Information — 5. Qualifications of Experts" in this Appendix [has] given and has not withdrawn their respective written consents to the issue of this document with the inclusion of certificates, letters, opinions or reports and the references to their respective names in the form and context in which they are respectively included.

7. Taxation of Holders of H Shares

(a) Hong Kong

The sale, purchase and transfer of H Shares are subject to Hong Kong stamp duty. The current rate charged on each of the purchaser and seller is 0.1% of the consideration or, if higher, the fair value of the H Shares being sold or transferred.

(b) Consultation with Professional Advisers

Potential **[REDACTED]** in the **[REDACTED]** are urged to consult their professional tax advisers if they are in any doubt as to the taxation implications of **[REDACTED]**, **[REDACTED]**, **[REDACTED]** or **[REDACTED]** of or **[REDACTED]** our H Shares (or exercising rights attached to them). None of our Company, our Directors, the Sole Sponsor, the **[REDACTED]**, the **[REDACTED]**, the **[REDACTED]**, the **[REDACTED]**, or any other person or party involved in the **[REDACTED]** accept responsibility for any tax effects on, or liabilities of, any person, resulting from the **[REDACTED]**, **[REDACTED]**, **[REDACTED]** or **[REDACTED]** of, **[REDACTED]** or the exercise of any rights in relation to our H Shares.

8. No Material Adverse Change

Our Directors confirm that, as of the date of this document, there has been no material adverse change in the financial or trading position of our Company since December 31, 2025 (being the latest balance sheet date of our consolidated financial statements as set out in the Accountants' Report).

9. Promoters

Save as disclosed in this document, within the two years preceding the date of this document, no cash, securities or other benefit has been paid, allotted or given or is proposed to be paid, allotted or given to any promoter in connection with the **[REDACTED]** and the related transactions described in this document.

10. Restrictions on Repurchase

For details, please see "Summary of the Articles of Association" in Appendix III to this document.

11. Binding Effect

This document shall have the effect, if an application is made in pursuance of it, of rendering all persons concerned bound by all of the provisions (other than the penal provisions) of **[REDACTED]** of the Companies (Winding Up and Miscellaneous Provisions) Ordinance so far as applicable.

12. Bilingual Document

The English and Chinese language versions of this document are being published separately, in reliance upon the exemption provided under section 4 of the Companies (Exemption of Companies and Prospectuses from Compliance with Provisions) Notice (Chapter 32L of the Laws of Hong Kong).

13. Miscellaneous

Save as otherwise disclosed in this document:

(a) within the two years preceding the date of this document, (i) our Company has not issued nor agreed to issue any share or loan capital fully or partly paid either for cash or for a consideration other than cash; and (ii) no commission, discount, brokerage or other special term has been granted in connection with the issue or sale of any shares of our Company;

(b) no Share or loan capital of our Company, if any, is under option or is agreed conditionally or unconditionally to be put under option;

(c) our Company has not issued nor agreed to issue any founder shares, management shares or deferred shares;

(d) our Company has no outstanding convertible debt securities or debentures;

(e) there is no arrangement under which future dividends are waived or agreed to be waived;

(f) there has been no interruption in our business which may have or have had a significant effect on the financial position in the last 12 months;

(g) our Company is not presently listed on any stock exchange or traded on any trading system; and

(h) our Company is a joint stock limited company and is subject to the PRC Company Law.